Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease

Z. Gatalica, S. Vranic, B. Krušlin, K. Poorman, P. Stafford, D. Kacerovska, W. Senarathne, E. Florento, E. Contreras, A. Leary, A. Choi, GK. In

. 2020 ; 9 (4) : 1441-1450. [pub] 20200103

Language English Country United States

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc21020761

BACKGROUND: Primary Extra-mammary Paget's disease (EMPD) is a very rare cutaneous adenocarcinoma affecting anogenital or axillary regions. It is characterized by a prolonged course with recurrences and eventually distant metastatic spread for which no specific therapy is known. METHODS: Eighteen EMPD (13 vulvar and five scrotal) and ten mammary Paget's disease (MPD) cases were comprehensively profiled for gene mutations, fusions and copy number alterations, and for therapy-relevant protein biomarkers). RESULTS: Mutations in TP53 and PIK3CA were the most frequent in both cohorts: 7/15 and 5/15 in EMPD; 1/6 and 4/7 in MPD HER2 gene amplification was detected in 4/18 EMPD (3 vulvar and 1 scrotal case) in contrast to MPD where it was detected in the majority (7/8) of cases. TOP2A gene amplification was seen in 2/12 EMPD and 1/6 MPD, respectively. Similarly, no difference in estrogen receptor expression was seen between the EMPD (4/15) and MPD (3/10). Androgen receptor was also expressed in the majority of both cohorts (12/16 EMPD) and (7/8 MPD).Here ARv7 splice variant was detected in 1/7 EMPD and 1/4 MPD cases, respectively. PD-L1 expression on immune cells was exclusively observed in three vulvar EMPD. In contrast to MPD, six EMPDs harbored a "high" tumor mutation burden (≥10 mutations/Mb). All tested cases from both cohorts were MSI stable. CONCLUSIONS: EMPD shares some targetable biomarkers with its mammary counterpart (steroid receptors, PIK3CA signaling pathways, TOP2A amplification). HER2 positivity is notably lower in EMPD while biomarkers to immune checkpoint inhibitors (high TMB and PD-L1) were observed in some EMPD. Given that no consistent molecular alteration characterizes EMPD, comprehensive theranostic profiling is required to identify individual patients with targetable molecular alterations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020761
003      
CZ-PrNML
005      
20210830102415.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.2820 $2 doi
035    __
$a (PubMed)31899853
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gatalica, Zoran $u Caris Life Sciences, Phoenix, AZ, USA
245    10
$a Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease / $c Z. Gatalica, S. Vranic, B. Krušlin, K. Poorman, P. Stafford, D. Kacerovska, W. Senarathne, E. Florento, E. Contreras, A. Leary, A. Choi, GK. In
520    9_
$a BACKGROUND: Primary Extra-mammary Paget's disease (EMPD) is a very rare cutaneous adenocarcinoma affecting anogenital or axillary regions. It is characterized by a prolonged course with recurrences and eventually distant metastatic spread for which no specific therapy is known. METHODS: Eighteen EMPD (13 vulvar and five scrotal) and ten mammary Paget's disease (MPD) cases were comprehensively profiled for gene mutations, fusions and copy number alterations, and for therapy-relevant protein biomarkers). RESULTS: Mutations in TP53 and PIK3CA were the most frequent in both cohorts: 7/15 and 5/15 in EMPD; 1/6 and 4/7 in MPD HER2 gene amplification was detected in 4/18 EMPD (3 vulvar and 1 scrotal case) in contrast to MPD where it was detected in the majority (7/8) of cases. TOP2A gene amplification was seen in 2/12 EMPD and 1/6 MPD, respectively. Similarly, no difference in estrogen receptor expression was seen between the EMPD (4/15) and MPD (3/10). Androgen receptor was also expressed in the majority of both cohorts (12/16 EMPD) and (7/8 MPD).Here ARv7 splice variant was detected in 1/7 EMPD and 1/4 MPD cases, respectively. PD-L1 expression on immune cells was exclusively observed in three vulvar EMPD. In contrast to MPD, six EMPDs harbored a "high" tumor mutation burden (≥10 mutations/Mb). All tested cases from both cohorts were MSI stable. CONCLUSIONS: EMPD shares some targetable biomarkers with its mammary counterpart (steroid receptors, PIK3CA signaling pathways, TOP2A amplification). HER2 positivity is notably lower in EMPD while biomarkers to immune checkpoint inhibitors (high TMB and PD-L1) were observed in some EMPD. Given that no consistent molecular alteration characterizes EMPD, comprehensive theranostic profiling is required to identify individual patients with targetable molecular alterations.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x antagonisté a inhibitory $x genetika $x metabolismus $7 D014408
650    _2
$a prsy $x patologie $7 D001940
650    _2
$a nádory prsu $x farmakoterapie $x genetika $x patologie $7 D001943
650    _2
$a variabilita počtu kopií segmentů DNA $7 D056915
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a amplifikace genu $7 D005784
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrosatelitní nestabilita $7 D053842
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a mutace $7 D009154
650    _2
$a extramamární Pagetova nemoc $x farmakoterapie $x genetika $x patologie $7 D010145
650    _2
$a Pagetova nemoc prsu $x farmakoterapie $x genetika $x patologie $7 D010144
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a skrotum $x patologie $7 D012611
650    _2
$a sekvenční analýza DNA $7 D017422
650    _2
$a kůže $x patologie $7 D012867
650    _2
$a nádory kůže $x farmakoterapie $x genetika $x patologie $7 D012878
650    _2
$a vulva $x patologie $7 D014844
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vranic, Semir $u College of Medicine, QU Health, Qatar University, Doha, Qatar
700    1_
$a Krušlin, Božo $u Ljudevit Jurak Department of Pathology and Cytology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia $u School of Medicine, University of Zagreb, Zagreb, Croatia
700    1_
$a Poorman, Kelsey $u Caris Life Sciences, Phoenix, AZ, USA
700    1_
$a Stafford, Phillip $u Caris Life Sciences, Phoenix, AZ, USA
700    1_
$a Kacerovska, Denisa $u Medical Faculty in Pilsen, Sikl's Department of Pathology, Charles University in Prague, Pilsen, Czech Republic $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Senarathne, Wijendra $u Caris Life Sciences, Phoenix, AZ, USA
700    1_
$a Florento, Elena $u Caris Life Sciences, Phoenix, AZ, USA
700    1_
$a Contreras, Elma $u Caris Life Sciences, Phoenix, AZ, USA
700    1_
$a Leary, Alexandra $u Gustave Roussy Cancer Center, INSERM U981, Paris, France
700    1_
$a Choi, April $u Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
700    1_
$a In, Gino K $u Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 9, č. 4 (2020), s. 1441-1450
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31899853 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102416 $b ABA008
999    __
$a ok $b bmc $g 1691354 $s 1141207
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 4 $d 1441-1450 $e 20200103 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options